Business Wire

SOLASIA-PHARMA

30.6.2021 10:00:07 CEST | Business Wire | Press release

Share
Solasia Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan

Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) today announced submission of a New Drug Application (NDA) for its new anti-cancer drug darinaparsin (generic name, development code: SP-02) as a treatment for relapsed or refractory peripheral T-cell lymphoma to the Ministry of Health, Labour and Welfare (MHLW). Based on positive results of R&D on darinaparsin, centered primarily on the results of the Asian Multinational Phase 2 Study (study results released in June 2020), Solasia filed an NDA for the drug with the regulatory authority in Japan ahead of anywhere else in the world.

Solasia expects to obtain regulatory approval in 2022 and to also launch in the same year. If approved and launched, darinaparsin would be the third drug Solasia successfully developed and brought to market since its founding and is expected to contribute to the treatment of PTCL.

Mr. Yoshihiro Arai, President and CEO of Solasia, commented as follows:
“No standard treatment has been established for relapsed or refractory PTCL as of yet. I firmly believe that darinaparsin, with its novel mechanism of action that differs from those of already approved drugs, will contribute to patients and healthcare providers at clinical sites as a new treatment option for relapsed or refractory PTCL. Since founding, Solasia has conducted R&D on five pipeline drugs. Of the five, we have successfully developed and brought to market two drugs, i.e., began providing them to patients, and today, we submitted an NDA for our first anti-cancer drug. Under our mission to provide patients with ‘Better Medicine for a Brighter Tomorrow’, we will continue aiming to contribute to patients’ treatment and enhanced quality of life. ”

About darinaparsin (SP-02)
Darinaparsin, an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors. The proposed mechanism of action of the drug involves the disruption of mitochondrial function, increased production of reactive oxygen species, and modulation of intracellular signal transduction pathways. Darinaparsin is believed to exert anticancer effect by inducing cell cycle arrest and apoptosis. Darinaparsin has been granted orphan drug designation in the US and EU.
For more information, please visit at https://solasia.co.jp/en/pipeline/sp-02.html

About Asian Multinational Phase 2 Study
The Asian Multinational Phase 2 Study was a multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of darinaparsin monotherapy in patients with relapsed or refractory PTCL conducted in Japan, Korea, Taiwan, and Hong Kong. (CT.gov Identifier: NCT02653976).
Solasia plans to present the results of the study at an international academic conference to be held in the near future.

About peripheral T-cell lymphoma (PTCL)
Please visit at https://solasia.co.jp/en/pipeline/sp-02.html

About Solasia
Please visit at https://solasia.co.jp/en/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OLX Launches Agentic AI Products to Transform Property Search and Car Sales at CLAIM AI in Lisbon25.2.2026 15:33:00 CET | Press release

OLX launches CompassGPT and AutoIQ, making OLX the leading verticalised platform scaling Agentic AI across the entire value chain - supporting millions of buyers while simultaneously empowering professional customers. The Agentic Products were unveiled at CLAIM AI in Lisbon, OLX’s premier flagship event, bringing together industry leaders to showcase practical, powerful AI innovation OLX’s leading investments and application of proprietary AI deliver faster, smarter, and more user-centric marketplace experiences, with more than 75 AI use cases already in the market, including 10 agentic AI use cases launched in H126 OLX Group, the largest and fastest growing platform for vertical transactions in Europe and South Africa, today unveiled two new Agentic AI-powered products at CLAIM AI, its invite-only Lisbon conference for marketplace innovators. Launching in key OLX markets, CompassGPT introduces a conversational assistant to real estate search, while AutoIQ provides dealers with automot

KleanNara Partners with Rimini Street to Accelerate Digital Transformation25.2.2026 15:00:00 CET | Press release

South Korea’s leading paper manufacturer cuts SAP ECC 6 and Oracle Database maintenance costs with Rimini Support™, freeing up funds and team focus for AI-driven innovation and growth Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced KleanNara has selected Rimini Street to provide support for its SAP ECC 6 and Oracle Database systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225123422/en/ KleanNara Partners with Rimini Street to Accelerate Digital Transformation Founded in 1966, KleanNara is one of South Korea’s leading manufacturers of paper and hygiene products. Holding a 25% share of the white cardboard market, the company is known for its commitment to quality, sustainability and innovation, and continues to expand globally with a focus on ESG-driven, eco-friendly products. Breaki

Axinn Adds Three Seasoned Antitrust Litigators, Reinforcing Trial Bench and West Coast Presence25.2.2026 15:00:00 CET | Press release

Hires Position Firm to Meet Rising Client Demand as Antitrust Enforcement Intensifies Axinn, Veltrop & Harkrider LLP announced today that Daniel Matheson, Katrina Rouse, and Jimmy Moore have joined its Antitrust practice as partners. Matheson arrives from the Federal Trade Commission (FTC), while Rouse and Moore join from the U.S. Department of Justice (DOJ) Antitrust Division. Rouse will join Axinn’s San Francisco office; Matheson and Moore will join the firm’s Washington, DC office. The additions strengthen Axinn's trial bench and West Coast practice as the firm continues to attract top antitrust talent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225403123/en/ Daniel Matheson (Left), Katrina Rouse (Center), and Jimmy Moore (Right) have joined Axinn, Veltrop & Harkrider's LLP Antitrust practice as partners. “Axinn continues to invest in top-tier talent and trial capabilities as we deepen our commitment to clients and

Stonebranch Unveils Latest Release of Universal Data Mover Gateway (UDMG), Advancing Orchestrated B2B MFT25.2.2026 15:00:00 CET | Press release

Secure, enterprise-grade B2B managed file transfer meets orchestration to automate full processes once files are sent or received Stonebranch, a leading provider of service orchestration and automation solutions, today announced the latest release of its Universal Data Mover Gateway (UDMG) — an enterprise-grade managed file transfer (MFT) solution purpose-built for secure, orchestrated B2B data exchange across hybrid landscapes. “In today’s enterprises, file transfer is not a standalone task. It’s the backbone of data pipelines, analytics, and critical business processes,” said Giuseppe Damiani, CEO of Stonebranch. “By orchestrating MFT alongside workload and infrastructure automation, Stonebranch turns file movement into a governed, observable, SLA-driven part of end-to-end enterprise workflows.” Secure, Modern B2B Managed File Transfer UDMG is designed specifically for external B2B data exchanges — where stringent security, regulatory compliance, SLA reliability, and diverse partner

Klarna Reaches 55 Million Monthly App Users as Usage Surges 53% Year Over Year25.2.2026 14:00:00 CET | Press release

Every day 9 million users use Klarna’s app to help them bank and pay Klarna, the global digital bank and flexible payments provider, is seeing a sharp rise in both monthly and daily app usage, as more consumers use the global digital bank’s services as part of their everyday money management. The Klarna app now reaches more than 55 million monthly active users globally, with 9 million people using the app on a daily basis. Daily engagement has increased by approximately 53% compared with last year, highlighting increasingly frequent use of Klarna’s banking, spending and shopping services. Sebastian Siemiatkowski, CEO and co-founder of Klarna: “When people use Klarna every day, it shows we’re delivering on our vision of becoming the global digital bank for the next generation. Consumers are using the app to stay on top of their spending and manage their money, which is exactly how we see Klarna evolving into an everyday money management app people rely on in daily life.” The massive app

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye